anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-20. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
The rate of change of NB, that is dNB/dt, is related to the changes in the amounts of A and B, NB can increase as B is produced from A and decrease as B produces C. Re-writing using the previous results:
CH2=CH2 + 3 O2 → 2 CO2 + 2 H2O, ΔH=−1327 kJ/mol (CH2CH2)O + 2.5 O2 → 2 CO2 + 2 H2O, ΔH=−1223 kJ/mol According to a kinetic analysis by Kilty and Sachtler, the following reactions describe the pathway leading to EO. In the first step, a superoxide (O2−) species is formed:
Amino acid dating is a dating technique used to estimate the age of a specimen in paleobiology, archaeology, forensic science, taphonomy, sedimentary geology and other fields. This technique relates changes in amino acid molecules to the time elapsed since they were formed. All biological tissues contain amino acids. All amino acids except glycine (the simplest one) are optically active, having an asymmetric carbon atom. This means that the amino acid can have two different configurations, "D" or "L" which are mirror images of each other. With a few important exceptions, living organisms keep all their amino acids in the "L" configuration. When an organism dies, control over the configuration of the amino acids ceases, and the ratio of D to L moves from a value near 0 towards an equilibrium value near 1, a process called racemization. Thus, measuring the ratio of D to L in a sample enables one to estimate how long ago the specimen died.
Sources: en.wikipedia.org
=== Pharmacokinetics === Drostanolone propionate is not active via the oral route and must be administered via intramuscular injection. The elimination half-life of the drug via this route is approximately 2 days. It has a much longer elimination half-life via intramuscular injection than drostanolone. Drostanolone propionate is metabolized into drostanolone, which is the active form.
Upon image analysis, the subcellular localization of the protein has been classified into one or more of 49 different organelles and subcellular structures. In addition, the resource includes an annotation of genes that display single-cell variation in protein expression levels and/or subcellular distribution, as well as an extended analysis of cell cycle dependency of such variations. The Cell Line resource contains information on genome-wide RNA expression profiles of human protein-coding genes in 1206 human cell lines, including 1132 cancer cell lines. The transcriptomics analysis includes classification based on specificity analysis across 28 cancer types, distribution and expression cluster analysis across all cell lines and for selected cancer types also analysis of similarity of the cell lines to their corresponding cancer type. The Structure resource contains information about the predicted three-dimensional structure of 19904 human proteins and their related isoforms. Interactive 3D protein structures based on predictions generated using the AlphaFold source code are shown with the possibility to highlight selected regions and positions in the structure. The Protein Browser tool displays a variety of features for the different isoforms and can be used to select splice variants and highlight protein related features such as known antigen sequences, transmembrane regions and InterPro domains directly on the structures.
Estrogen also causes the laying down of fat in the development of the secondary sex characteristics. This contributes to the maturation of the vulva with increases in the size of the mons pubis, and the labia majora and the enlargement of the labia minora.
Sources: en.wikipedia.org
== Metabolism == Metabolism of 1,3-dibromopropane was examined in 1981. The examination was done by orally administering 1,3-dibromopropane to rats and collecting results 24 hours after administration. Results were obtained from three sources: urine, faeces, and expired air. Upon analysis of the urinary results, researchers discovered the formation of metabolite, N-acetyl-S-(1-bromo-3-propyl)-cysteine and the decline in the GSH content of the liver of the rats. This led to the assumption that 1,3-dibromopropane could have reacted with GSH after administration and gave rise to 1-bromo-3-propyl-S-glutathione, which ultimately form the urinary metabolite. Moreover, due to little radioactivity observed from feces and the confirmation from maintained blood levels of radioactivity proved the occurrence of biliary excretion of sulfur-containing metabolites and enterohepatic cycling.
Amphetamine-Dextroamphetamine is known to hamper appetite. Amphetamine-Dextroamphetamine is used to treat Attention deficit hyperactivity disorder (ADHD) and is usually under the trade name "Adderall" or "Mydayis". Amphetamine sulfate (also known as amfetamine) – US FDA-approved for the treatment of exogenous obesity under the brand name "Evekeo". Methylphenidate Cocaine Caffeine Glucomannan Leptin Lisdexamfetamine - US FDA approved for the treatment of binge-eating disorder in adults under the brand name "Vyvanse". Methamphetamine hydrochloride – USFDA-approved for the treatment of obesity (as a short-term) under the brand name "Desoxyn". Nicotine Liraglutide as brand name Saxenda Semaglutide (brand name Ozempic/Wegovy) GLP-1 agonist Tirzepatide (Brand Name Mounjaro, Zepbound) Metformin Opiates/opioids such as heroin, morphine, codeine, oxycodone, fentanyl, etc. Anti-obesity medication
=== Accolades === In 2004, IGN named Bloodlines the Best PC RPG of that year and GameSpy called the "Ocean House Hotel" quest the Level of the Year. In 2005, Computer Gaming World called it the Role Playing Game of 2004, saying that it offered "a deep, balanced character creation system, a truckload of interesting quests, a good story and great NPCs to interact with." Computer Games Magazine nominated Bloodlines for its 2004 "Best Writing" award; the award went to Half-Life 2. During the 8th Annual Interactive Achievement Awards, the Academy of Interactive Arts & Sciences nominated Bloodlines for "Computer Role-Playing Game of the Year".
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.